# Clinical characteristics and long-term outcomes of 101 patients with urea cycle disorders in China

**Authors:** Ziyan Cen, Pingping Ge, Yuhe Chen, Ting Zhang, Peiyao Wang, Lingwei Hu, Benqing Wu, Xinwen Huang

PMC · DOI: 10.1186/s13023-025-03985-w · Orphanet Journal of Rare Diseases · 2025-08-13

## TL;DR

This study examines the clinical features and outcomes of 101 Chinese patients with urea cycle disorders, emphasizing the benefits of newborn screening for early diagnosis and better treatment outcomes.

## Contribution

This is the first large-scale study on urea cycle disorders in China, providing insights into clinical features and the impact of newborn screening.

## Key findings

- 93% survival rate observed among urea cycle disorder patients.
- 57% of patients were diagnosed through newborn screening, which improved outcomes.
- Neurological and gastrointestinal symptoms were most common, often appearing in the first month of life.

## Abstract

Urea cycle disorders (UCDs) are a group of rare genetic metabolic disorders characterized by hyperammonemia, which can lead to neurological damage, systemic complications, and even death. Understanding UCDs’ clinical features and progression in the Chinese population will fill research gaps and benefit patients globally.

This retrospective study evaluated the clinical, biochemical, genetic characteristics, and long-term outcomes in 101 Chinese patients with six subtypes of UCDs between 2007 and 2024. Data were collected from medical records and analyzed.

The overall survival rate was 93.0% among UCD patients. An equal gender ratio was observed in ornithine transcarbamylase deficiency. Newborn screening (NBS) was conducted in this cohort, and 57.0% of patients were diagnosed through NBS. Neurological and gastrointestinal symptoms were the most common. Symptoms often appeared within the first year, especially in the first month. Arginine was the most frequently used treatment, with glycerol phenylbutyrate often used as a nitrogen scavenger in severe cases. Biochemical analysis showed subtype-specific differences, including notable declines in leucine and glycine on low-protein diets. Genetic analysis revealed a wide distribution of mutations, with few hotspots and 17 newly identified mutations. Clinically diagnosed patients had worse outcomes than those diagnosed via newborn screening.

This study is the first to describe the clinical features and long-term outcomes of UCDs in a large sample of Chinese patients, highlighting the importance of newborn screening for early diagnosis and improved treatment outcomes.

The online version contains supplementary material available at 10.1186/s13023-025-03985-w.

## Linked entities

- **Chemicals:** arginine (PubChem CID 232), glycerol phenylbutyrate (PubChem CID 10482134), leucine (PubChem CID 857), glycine (PubChem CID 750)
- **Diseases:** urea cycle disorders (MONDO:0004739)

## Full-text entities

- **Genes:** ASL (argininosuccinate lyase) [NCBI Gene 435] {aka ASAL, ASLD}, CCDC6 (coiled-coil domain containing 6) [NCBI Gene 8030] {aka D10S170, H4, PTC, PTC1, TPC, TST1}, ARG1 (arginase 1) [NCBI Gene 383], CPS1 (carbamoyl-phosphate synthase 1) [NCBI Gene 1373] {aka CPS1D, CPSASE1, GATD6, PHN}, ASS1 (argininosuccinate synthase 1) [NCBI Gene 445] {aka ASS, CTLN1}, SLC25A15 (solute carrier family 25 member 15) [NCBI Gene 10166] {aka D13S327, HHH, LNC-HC, ORC1, ORNT1}, OTC (ornithine transcarbamylase) [NCBI Gene 5009] {aka OCTD, OTC1, OTCD, OTCase}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}
- **Diseases:** malnutrition (MESH:D044342), ASLD (MESH:D056807), neurological impairment (MESH:D009422), N-acetylglutamate synthase deficiency (MESH:C536109), coma (MESH:D003128), vomiting (MESH:D014839), neurological damage (MESH:D020196), Intellectual and motor impairments (MESH:D008607), growth retardation (MESH:D006130), death (MESH:D003643), lethargy (MESH:D053609), metabolic diseases (MESH:D008659), amino acid abnormalities (MESH:D000592), OTCD (MESH:D020163), seizures (MESH:D012640), diarrhea (MESH:D003967), Gastrointestinal symptoms (MESH:D012817), neurotoxic (MESH:D020258), NBS (MESH:D006475), ASSD (MESH:D020159), UCDs (MESH:D056806), neuroimaging abnormalities (MESH:D000014), behavioral disorders (MESH:D001523), genetic (MESH:D030342), intellectual and motor developmental impairments (MESH:C565406), overweight (MESH:D050177), CPS1D (MESH:D020165), encephalopathy (MESH:D001927), HHHS (MESH:C538380), neurological abnormalities (MESH:D009461), HA (MESH:D022124), ARG1D (MESH:D020162), developmental delays (MESH:D002658), multiorgan failure (MESH:D051437), motor impairments (MESH:D000068079), Citrin D (MESH:C538053)
- **Chemicals:** GPB (MESH:C570223), Amon (MESH:D000641), Orn (MESH:D009952), BCAA (MESH:D000597), Arg (MESH:D001120), amino acid (MESH:D000596), ASA (MESH:D001125), Sodium benzoate (MESH:D020160), urea (MESH:D014508), Leu (MESH:D007930), NaPBA (MESH:C110175), Cit (MESH:D002956), Nitrogen (MESH:D009584), Sodium phenylbutyrate (MESH:C075773), Gly (MESH:D005998), LO (-), NO (MESH:D009614), Val (MESH:D014633)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** p.R307C, 1168G>A, 140dupA, 255C>G, 706C>T, c.970+5G>A, p.R111W, p.R71T, 119G>A, p.T284I, c.719-1G>C, 862G>T, p.G162E, 1436C>T, 1019C>T, c.1176_1178del, 870delT, 1864G>A, c.466-5delTT, p.P156L, 912G>T, p.R168C, c.67C>T, c.390_403del, c.514-35C>G, 151G>A, p.S18L, 3443T>A, c.353dup, p.G193R, p.H214R, c.466-6_466-5del, c.867+1G>A, p.L118Ffs*5, 594C>G, p.T90I, p.R279Q, 799A>C, p.L201P, p.R308W, 133G>A, 694C>T, p.E258K, c.77+5G>A, 256C>T, c.268C>T, 383A>T, 544C>T, p.D128V, 544G>A, p.V1011M, G39C, p.D763Y, 587A>T, p.Y259H, p.G288W, p.D196Y, c.929_931del, p.V311M, 2359C>T

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12351844/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12351844/full.md

## References

4 references — full list in the complete paper: https://tomesphere.com/paper/PMC12351844/full.md

---
Source: https://tomesphere.com/paper/PMC12351844